

WHERE LIFE SCIENCE MEETS MONEY | INVESTORS UNCOVER INNOVATION | PHARMA SEEK PARTNERS

biotechandmoney LONDON

3-4 February 2015 | etc.Venues, 155 Bishopsgate, London

GOLD SPONSOR



SILVER SPONSORS



ASSOCIATE SPONSORS



biotechandmoney
bringing deals to life



WHAT IS BIOTECH AND MONEY LONDON

**Where Life Science meets money.
Investors uncover innovation.
Pharma seek partners.**

Biotech and Money London is a two-day congress providing the education, strategies and solutions you need to enable more effective funding, investment, business planning and partnering within your business.

It's a congress like no other. It brings deals to life.

5 REASONS TO ATTEND

Access capital. Find investors, funding sources and partners.

Leave with new ideas from genuine Peer-2-Peer congress formats.

Find the real sources of innovation. Meet the innovators, inventors and entrepreneurs with commercial potential.

Networking, partnering and business development opportunities galore.

Real market insight: what's driving UK Life Science and what's attracting investors.

WHAT'S IN IT FOR ME



LIFESCIENCE

Entrepreneurs and CxO's can:

Generate new ideas in peer-to-peer congress formats across any stage of the funding and investment lifecycle.

Learn from generations of life science executives who've been there and done it.

Get maximum exposure with elevator pitches on the online portal to be viewed by investors and pharma.

Find partners through 1-2-1 meetings to ensure you have those all important face-to-face discussions.



INVESTORS

Active and new-to-sector investors can:


Engage with entrepreneurs to assess early stage research for commerciality.

Meet SME bioscience executives who are ripe for funding and investment.

Access life science elevator pitches to qualify attending bioscience companies.

Attend market sector sessions outlining the hottest investable areas in the UK.

Arrange 1-2-1 meetings to ensure you ID and open up discussions with new science.



PHARMA

BD&L, Partnerships and M&A execs can:

Engage with entrepreneurs to access untapped channels of early stage research.

Meet SME bioscience players who offer up novel licensing and partnership opportunities.

Access bioscience elevator pitches to qualify attending bioscience companies.

Meet MidCap private and public life science companies with M&A potential.

Arrange 1-2-1 meetings to ensure you ID and open up discussions with new partners.



SERVICES

Places for financial and professional services make up <10% of total tickets.

Engage hundreds of life science executives to find new clients.

Invite and arrange meetings to have those all important face-to-face client discussions.

Attend market sector sessions outlining the hottest growth areas in the UK.

Use the informal networking opportunities to maximise introductions.

HOW WE ARE DIFFERENT



EXCLUSIVE AUDIENCE

A qualified executive-level audience.

Heavy buy side dynamic. Sell side represents <10% of the audience.

We keep the profile dynamic focused on life science and money.



NEW FORMATS

We don't do powerpoint.

Peer-to-peer formats to share knowledge and experience.

Content that offers both strategic and practical take aways.



NEW PLAYERS

We attract grass roots inventors, innovators and entrepreneurs.

We develop sessions for companies in any stage of their funding / investment lifecycle.



ELEVATOR PITCHES

We offer online elevator pitches to attending life science companies.

We give portal access to Investors and Pharma to help them with S&E.



REAL TAKE-AWAYS

We produce detailed post event reports of all sessions.

We conduct live polls and onfloor voting sessions during the congress.



A 365 APPROACH

Our 1-2-1 Partnering system remains open until Jan 2016.

Elevator pitches remain live for as long as the partnering system is live.

ONLINE PRESENTATION SHOWCASE

We've created an online portal for life science companies to upload a 7min, 7-slide audio presentation that can be viewed by attending Investors and Pharma, privately and securely. It's the perfect profiling and promotion tool.

Presentations go live a week before the congress.

Benefits to Bioscience Companies

- Introduce your research / company to an engaged audience
- Outline your research / company USPs
- Present your company strategy and goals
- Highlight investment, licensing or partnership requirements

Benefits to Investors and Pharma

- No need to spend your conference time in biotech showcases
- Evaluate new bioscience players not already on the circuit
- A pre-qualification tool that helps you select your 1-2-1s



TESTIMONIALS

"I am excited to be part of Biotech and Money's advisory board and helping them find new ways to support the ambitions of entrepreneurs to build sustainable biotech companies via the access of aligned and relevant financing sources. They bring fresh ideas, insightful content and run impacting events and have a key role to play in helping the industry move forward."

Dr Darrin M Disley, CEO, Horizon Discovey Group plc

"Biotech and Money produces high quality content and events that offer outstanding opportunities for investors, bioscience companies and stakeholders to connect and learn from each other. We are delighted to be a sponsor and partner."

Nigel Pitchford, Chief Investment Officer, Imperial Innovations

CONGRESS FORMATS



KEYNOTE SESSIONS

20 min presentations from life science pioneers. No powerpoint.

Inspirational, thought provoking, game changing content and delivery.



GROUP DISCUSSIONS

45 min themed discussion groups on key elements of the funding lifecycle.

Genuine executive level peer-to-peer debate, discussion and outcomes.



ROUNDTABLES

40 min roundtables on specific industry challenges and opportunities.

Intimate, immersive and interactive. Gain genuine practical advice.



THEMED SESSIONS

Game changing thematic panels that highlight emerging hot opportunities.

Engage in Q&A and interact with a qualified panel of industry experts.



1-2-1 PARTNERING

1-2-1 Partnering system to search, evaluate and arrange onsite meetings.

Formal sessions to meet your next client and develop business relationships.



NETWORKING

Over 12hrs of informal networking time during the 2-day congress.

Refreshments, networking drinks and seated VIP Gala Dinner.



AGENDA

KEYNOTES AND TESTIMONIALS



George Freeman, Minister for Science, Department of Health, UK

George was elected to Parliament in 2010 after a 15 year career across the life sciences sector, in particular working with hospitals, clinical researchers, patient groups, and biomedical research companies to pioneer novel healthcare innovations.

On July 15, George was appointed as Minister for Life Sciences, a Parliamentary Under-Secretary of State at the Department of Health and Department of Business, Innovation and Skills. His mission is to make the UK the best place in the world to discover and develop 21st Century healthcare innovations.

"I am excited to be supporting and speaking at this terrific event. It is a real opportunity to build partnerships, share insight and highlight vibrancy in the UK Life Science sector, with over £700m investment in early stage ventures in the first half of this year."

George Freeman, Minister for Science, Department of Health, UK



Dr Zahid Latif, Head of Healthcare, Innovate UK

Dr Zahid Latif began his career as a pharmacist in 1992, and after a stint in hospital pharmacy, went on to complete a PhD in pharmaceutical chemistry. He then spent 11 years in R&D and operations management, working with biotech companies such as Xenova, MNL & Integrin and multinationals such as Wyeth. He joined the UK Technology Strategy Board in Oct 2007 as Lead Technologist in Medicines and Healthcare, becoming Head of Healthcare in 2010.

"Biotech and Money is a brilliant initiative that is helping support finance, funding and partnerships for the biotech industry. Their February event is going to be an incredible gathering of the finest minds in the sector and I am delighted to be speaking at it."

Dr Zahid Latif, Head of Healthcare, Innovate UK



Nicola Mather, Director, Office of Life Sciences, BIS

Dr Mather took up her role as Director of the new Office for Life Sciences in 2014. The Office was formed by a merger of the Department for Business, Innovation and Skills and the Department of Health Units that previously oversaw life sciences policy. The new joint Office for Life Sciences leads the government's efforts to make the UK the best place to invest in life sciences research whilst improving health-care. The OLS works closely with a range of other organisations including UKTI, Innovate UK, Research Councils UK, MHRA, NICE and NHS England to help stimulate economic growth in the Life Sciences industries and to support uptake of new cost-effective products and processes in the NHS to improve patient outcomes.

Previously, Dr Mather was a director in Deloitte's Healthcare and Life Sciences Strategy Consulting Practice. Dr Mather has a DPhil in Neuroscience from the University of Oxford.



Keith Thompson, Chief Executive, Cell Therapy Catapult

Keith Thompson was appointed Chief Executive of the Cell Therapy Catapult, part of a Technology Strategy Board initiative to improve UK economic capability by bridging the gap between academic invention and commercialisation, in May 2012.

Keith joined the Catapult from the Scottish National Blood Transfusion Service where he was National Director, focusing on modernising the blood supply, and expanding the service into cell therapy. Prior to this, Keith held various senior domestic and international positions where he grew several biomanufacturing businesses to become global players.



Sir Chris Evans, Chairman, Excalibur Group

Sir Chris is regarded as one of Europe's leading biotechnology entrepreneurs. He has a proven track record of establishing successful, high-quality science companies, 20 of which have been taken public. These companies have made substantial returns for their venture capital and institutional backers and employ more than 3,500 people. Of particular note is Chiroscience plc, started by Sir Chris with £1m in 1992 and grew to £600m by 1997 before merging with Celltech plc, which in turn has merged with UCB to create one of Europe's flagship bioscience enterprises.

"Biotech and Money London is a powerful combination of top-notch scientific thinking and savvy business people. It promises to be a terrific event and I look forward to being part of a stimulating debate and continuing commercial success for the sector."

Sir Chris Evans, Chairman, Excalibur Group



David Roblin, Chief Operating Officer, The Francis Crick Institute

David joined the Crick in September 2014. As well as taking on the role of COO, David will also lead translational activities for the Crick as it accelerates its science for health and wealth benefits. David practiced medicine for 5 years before entering the Pharmaceutical Industry. He has held significant leadership roles in his pharmaceutical career, with general management, research, development and commercial responsibilities. He was formerly SVP, Head of Research for Pfizer's European R&D. David has been Chief Medical Officer and a Non-Executive Director to a number of Biotechs.

He also serves on the Major Awards Committee of the UK's Biomedical Catalyst Fund. David has a degree in Biochemistry from University College London and later qualified in Medicine from St George's Hospital. He is a Fellow of the Royal College of Physicians, a member of the Faculty of Pharmaceutical Medicine and an honorary Professor at Swansea University.

CONFIRMED SPEAKERS INCLUDE



Keith Blundy
CEO
Cancer
Research
Technology



**Meindert
Boysen**
Programme
Director
Technology
Appraisals
NICE



Adrian Bull
Managing
Director Imperial
Health Partners



Andrew Chitty
Executive
Director
Digital Life
Sciences



Darrin Disley
CEO
Horizon
Discovery Group



**Steven
Dodsworth**
CEO
D Health



Matthew Durdy
CBO
Cell Therapy
Catapult



Andrew Elder
Partner
Albion Ventures



Sam Fazeli
Head of
European
Research,
Pharmaceuticals
Analyst
Bloomberg



Alasdair Gaw
Lead Specialist,
Stratified
Medicine
InnovateUK



Christian Girard
CEO
ABCrowdFund-
ing Advisors



David Grainger
Venture Partner
Index Ventures



Beverley Carr
VP, BD
Immunoinflam-
mation Therapy
Area GSK



**Deborah
Harland**
Partner
SR-One



Bruce Hellman
CEO
uMotif



**Chris
Hollowood**
Partner
Syncona
Partners



Robert James
Managing
Partner
Sixth Element
Capital



Peter Johnson
Chief Clinician
Cancer
Research UK



Roel Bulthuis
Head
MS Ventures



Mike Capaldi
Commercialisa-
tion Director
**Edinburgh
BioQuarter**



Sue Dunkerton
Director
KTN-UK



Sinclair Dunlop
Managing
Partner Epidarex



Gary Ford
CEO
Oxford Academic
Health Science
Network



**Prof. Sarah
Garner**
Associate
Director
Research and
Development
NICE



Vishal Gulati
Venture Partner
DFJ Esprit



Stefan Hamill
Analyst,
Healthcare and
Life Sciences
Peel Hunt



Olav Hellebo
CEO
ReNeuron



Tony Hickson
Managing
Director,
Technology
Transfer
Imperial
Innovations



Martin Judge
Innovation
Sourcing
Director
Novo Nordisk



Simon Kerry
CEO
Karus
Therapeutics



**Mette Kirstine
Agger**
Managing
Partner
LundbeckFond
Ventures



Anja Konig
Managing
Director Novartis
Venture Fund



Eddie Littler
CEO
Domainex



Francois Meyer
Advisor to the
President,
International
Affairs
HAS



Berndt Modig
CFO
Prosensa



**Nicola
Baker-Munton**
CEO
Stratagem IPM



Nooman Haque
Director of Life
Sciences,
Europe
Silicon Valley
Bank



Mike Chambers
Head of
Reimburse-
ment and Value
Demonstration
GSK



Mene Pangalos
Executive Vice
President
Innovative
Medicines and
Early Research
AstraZeneca



Simon Russell
CBO
Creabilis



Sue Staunton
Partner
James Cowper



Iain Thomas
Head of
Life Sciences
Cambridge
Enterprise

CONFIRMED SPEAKERS INCLUDE




Martin Walton
CEO
Excalibur Group



Elaine Warburton
CEO
QuantuMDx



Charles Weston
Director,
Healthcare Equity Research
Numis Securities



Paul Jones
CEO
Genomics
England



Mike Messenger
Deputy Director
and Scientific
Manager
NIHR Diagnostic
Evidence
Co-Operative



Matthew Walls
CEO
Epistem



Karen Livingstone
National Director
for the Small
Business
Research
Initiative - SBRI
Healthcare DoH



Dan Mahoney
Fund Manager
Polar Capital



Freddy Crossley
Director
Investment
Banking
Panmure Gordon



Ian Nicholson
CEO
F2G



Nigel Pitchford
CIO
Imperial
Innovations



David Porter
Managing
Partner
Apposite Capital



Ian Tracey
Head of Access
to Funding and
Finance
KTN UK



Patrick Verheyen
Head
J&J
Innovation
Centre London



Brian White
Head of
Healthcare
Shore Capital



Penny Wilson
Innovation
Platform Leader
– Stratified Medi-
cine InnovateUK



Graziano Seghezzi
Partner
Sofinnova
Partners



Ashwani Bahl
Senior
Director, Global
Ext. R&D
Lilly



Jane Dancer
CBO
F-Star



Neill MacKenzie
CEO
Trimunocor



Ed Hodgkin
CEO
Autolus Ltd.



Nick Scott-Ram
Director of
Commercial
Development
OAHNS



**Prof. Sir Martin
Evans**
Chairman and
CSO
Cell Therapy Ltd.



**Ajan
Reginald**
Executive
Director and
Co-Founder
Cell Therapy Ltd.



Mick Cooper,
Head of
Research,
Healthcare
Edison
Investment
Research



Mark Dunne
Reporter
Shares



Andrew Ward
Pharmaceutical
Correspondent
Financial Times



Kevin Johnson
Partner
Index Ventures



Lorna Green
Commercial
Director
North West
Coast AHSN



Elaine Evans
Lead
Technologist,
Medicines and
Healthcare
Innovate UK



**Asaf
Homossany**
Managing
Director, EMEA
NASDAQ



David Phillips
Partner
SR-One



**Surani
Fernando**
Acting Editor,
EMEA
BioPharm
Insight



**Prof. Martin
Glennie**
Professor of Im-
munochemistry
University of
Southampton



Tamar Ghosh
Lead, Longitude
Prize
Nesta



Dr Chris Butler
Professor of
Primary Care
Medicine
University of
Cardiff

SPECIAL GALA DINNER SPEAKERS



**Prof. Dame
Sally Davies**
Chief Medical
Officer for
England
DoH



Anil Vaidya
Founder
SCANurse

DAY ONE - 3RD FEBRUARY 2015

08:00 Registration and morning refreshments

09:00 Chairman's opening remarks: **Andrew Ward**, Pharmaceutical Correspondent, Financial Times



09:10 Opening Keynote Address

- Exploring a world-leading science base and pioneering work in healthcare technology to make the UK the global hub for medical innovation and patient empowerment
- Developing and delivering a framework that supports early stage research and development

George Freeman, Minister for Sciences, Department of Health, UK



09:20 Keynote Panel: The Future of Life Sciences Investment in the UK

- The political and strategic perspective on health and industrial investment and growth policies
- How can the UK drive the Life Science investment agenda
- Innovation, how can the combined eco-system stimulate investment and growth

Andrew Ward, Pharmaceutical Correspondent, Financial Times (**Chair**)

George Freeman, Minister for Sciences, Department of Health, UK

Zahid Latif, Head of Healthcare, InnovateUK

Nicole Mather, Director, Office for Life Sciences, Department of Health

Keith Thompson, Chief Executive Officer, Cell Therapy Catapult

Sir Chris Evans, Chairman, Excalibur Group

10:15 Morning refreshments and networking

ANATOMY OF A START-UP



ANATOMY OF A GROWTH COMPANY

10:45 Technology Transfer and Commercialisation

Tech Transfer approaches; getting the most from development funding, intellectual property protection, company formation and licensing your technology.

Mike Capaldi, Commercialisation Director, Edinburgh BioQuarter (**Chair**)

Tony Hickson, MD, Tech Transfer, Imperial Innovations

Iain Thomas, Head, Life Sciences, Cambridge Enterprise

Patrick Verheyen, Head, J&J Innovation Centre London

Mene Pangalos, EVP, Innovative Medicines and Early Research, AstraZeneca

David Phillips, Partner, SR-One

10:45 Follow-On and Growth Capital

What are the characteristics that make a biotech investable and what makes for a great asset? What have VCs backed and why? The power of syndication. Asset centric vs. ex-pharma assets

Joe Pillman, Partner, Wilmer Hale (**Chair**)

Nigel Pitchford, CIO, Imperial Innovations

Martin Walton, CEO, Excalibur Group

Chris Hollowood, Partner, Syncona Partners

David Porter, Partner, Apposite Capital

Graziano Seghezzi, Partner, Sofinova Partners

Ian Nicholson, CEO, F2G

11:30 Translational and Start-up Capital

Strategies to win government grants. Where are the new sources of start up capital and how can bioscience access them? Options for dilutive and non dilutive funding. Novel and fully integrated approaches to partnerships. Role of VCs and Corporates in working with Angels.

Ashwani Bahl, Vice President External Innovation & Venture Partnerships, Lilly (**Chair**)

Ian Tracey, Head of Access to Funding & Finance, KTN

Sinclair Dunlop, Managing Partner, Epidarex

Robert James, Managing Partner, Sixth Element Capital

David Grainger, Venture Partner, Index Ventures

Elaine Warburton, CEO, QuantuMDx

11:30 Corporate Venture Capital

The role of CVCs in bioscience. CVC engagement. Adding value beyond financial investors. What CVCs look for in an investment. Lessons learned in working with CVCs.

Nooman Haque, Director of Life Sciences, Europe, Silicon Valley Bank (**Chair**)

Deborah Harland, Partner, SR-One

Roel Bulthuis, Managing Director, MS Ventures

Mette Kirstine Agger, Managing Partner, LundbeckFond

Anja König, Managing Director, Novartis Venture Fund

12:15 AHSNs: Innovation to Adoption

Making the journey from Innovation to Adoption; the role of SBRI and AHSNs, building partnerships and understanding NHS transformations.

Karen Livingstone, National Director for the Small Business Research Initiative - SBRI Healthcare, DoH (**Chair**)

Gary Ford, CEO, Oxford AHSN

Adrian Bull, Managing Director, Imperial Health Partners

Lorna Green, Commercial Director, North West Coast AHSN

12:15 Licencing and Partnerships

What does big pharma want from biotech and vice versa? Are asset-centric vehicles more attractive? How can you maximise mutual benefit in partnerships? What are the most innovative deal making structures that are working? Licencing as an alternative exit.

Joe Pillman, Partner, Wilmer Hale (**Chair**)

Keith Blundy, CEO, Cancer Research Technology

Simon Kerry, CEO, Karus Therapeutics

Eddy Littler, CEO, Domainex

Simon Russell, CBO, Creabilis

Martin Judge, Innovation Sourcing Director, Novo Nordisk

13:00 Networking lunch



14:00 Roundtables (14:05 and 14:50)

Role of adoption in the innovation pathway
Nick Scott-Ram, Director of Commercial Development, OAHSN

1) Clearing the path to market - Freedom to operate

2) Ensuring ROI on IP investment

Nicola Baker-Munton, CEO, Stratagem IPM

1) Due diligence: investor/buyer/seller perspective - James Robertson, Partner, Marks & Clerk

2) Valuing IP in the 21st century - Kelvin King, Principal, Marks & Clerk Consulting

How and when to prepare for an IPO

Sue Staunton, Partner, James Cowper



14:00 Biomedical Catalyst Review

Representatives from Innovate UK and the Biomedical Catalyst will examine the process as well as the economic impact on the funding landscape and invite discussion on what delegates would like to see as improvements to the scheme.

Elaine Evans, Lead Technologist,

Medicines and Healthcare, Innovate UK

Bruce Colley, Access to Finance Manager, Innovate UK

14:00

**Closed Door
Publicly Listed
CEO Forum**
(Invite only)

See page 17

15:30 Afternoon refreshments



16:00 Creating the 'Win, Win, Win': Anatomy of an IPO

Horizon Discovery secured £68.6m to fuel global growth through an IPO in March 2014 on London's AIM. Hear the successful approach taken by the company and the lessons learned during the IPO process.

Darrin Disley, CEO, Horizon Discovery Group, **Richard Vellacott**, Chief Financial Officer, Horizon Discovery Group, **Freddy Crossley**, Director, Investment Banking, Panmure Gordon



16:40 Approaching IPO and Public Markets: AIM, NASDAQ and Euronext

Drawing comparisons from listing on AIM, Ndaq and Euronext. How can bioscience properly prepare for IPO? How should you approach and think about your valuation? What are the most common mistakes to avoid? Post IPO considerations and positioning for growth.

Asaf Homossany, Managing Director, EMEA, NASDAQ, (**Chair**) **John Burt**, CEO, Abzena, **Berndt Modig**, CFO, Prosensa, **Eduardo Bravo**, CEO, Tigenix, **Dan Mahony**, Fund Manager, Polar Capital



17:20 What Pharma want: Anatomy of a Deal

How has M&A been brought earlier into the R&D lifecycle? M&A vs. IPO decision-making: when and why should you opt for a trade sale. How to best structure and optimise an M&A deal for mutual benefit? How to reconcile relative valuations? How is risk affecting deal making decision in the current climate?

Surani Fernando, Acting Editor EMEA, BioPharm Insight, **Beverley Carr**, VP Business Development, Immunoinflammation, GSK, **Kevin Johnson**, Partner, Index Ventures, **Ajan Reginald**, Executive Director, Cell Therapy Ltd, **Jane Dancer**, CBO, F-Star

18:00 Close of Day One followed by Drinks Reception and Life Science Futures Gala Dinner (see page 19)

DAY TWO - 4TH FEBRUARY 2015

08:00 Morning refreshments

09:00 Chairman's opening remarks



09:10 Keynote Address: Developing and delivering bold new approaches to translation in the UK

- Capitalising and exploiting IP generated in institutes and turn that into commercial viability
- The benefits of an inter disciplinary approach
- How to engender a culture conducive to applied science
- How to fund the development and commercialisation of translatable science

David Roblin, Chief Operating Officer, The Francis Crick Institute



09:30 Accelerating the development and uptake of Precision Medicine in the UK

- Driving the shift to Precision Medicine by making commercialisation easier in the UK
- Taking precision medicine products into testing in clinical settings and de-risking for further investment
- Simplifying and accelerating Precision Medicine product development, help create new companies and attract inward investment by large life science companies

Alasdair Gaw, Lead Specialist, Stratified Medicine, InnovateUK **(Chair)**

Penny Wilson, Innovation Platform Leader – Stratified Medicine, InnovateUK

Paul Jones, CEO, Genomics England

Mike Messenger, Deputy Director and Scientific Manager, NIHR Diagnostic Evidence Co-Operative

Matthew Walls, CEO, Epistem



10:15 Digital Health: What it means for the future of R&D in the UK

- Stimulating innovation in the UK digital health sector and translating successful Digital Health projects
- Healthcare policy and the regulations and reimbursement within the Digital Health market
- What's hot and what's not in Digital Health

Sue Dunkerton, Director, KTN-UK **(Chair)**

Steven Dodsworth, CEO, D Health


Bruce Hellman, CEO, uMotif

Andrew Chitty, Co-Founder, Digital Life Sciences

Vishal Gulati, Venture Partner, DFJ Esprit

Andrew Elder, Partner, Albion Ventures

11:00 Morning refreshments and networking



11:40 Growing a UK Cell and Advanced Therapy industry

- How do we drive the delivery of investable UK propositions in cell therapy
- Addressing the challenges to commercialisation of intellectual property in the cell therapy sector
- Looking within and beyond the UK to increase inward investment
- Addressing the risks associated with investing in cell therapy


Matthew Durdy, CBO, The Cell Therapy Catapult **(Chair)**

Prof. Sir Martin Evans, Chairman and CSO, Cell Therapy Ltd.

Olav Hellebo, CEO, ReNeuron

Ajan Reginald, Executive Director and Co-Founder, Cell Therapy Ltd.

Mick Cooper, Head of Research, Healthcare, Edison Investment Research



12:25 Immuno-oncology - priming a super blockbuster market

- What are the most promising opportunities in Immuno-oncology?
- Target toxicity as a predictor of positive therapeutic outcome
- How do you see the CAR T cell approach achieving regulatory approval?
- How do you see the approach fitting into the different re-imbursement mechanisms around the globe?
- Should we be open minded about other immune modulatory therapeutics?

John Hodgson, Editor, SCRIP (Chair)

Prof. Martin Glennie, Professor of Immunochemistry, University of Southampton

Bjorn Frendeus, Vice President, Preclinical Research, Bioinvent

Ed Hodgkin, CEO, Autolus Ltd.

Neill MacKenzie, CEO, Trimunocor, CBO, Biotechnol

13:10 Networking lunch



14:10 The Longitude Prize Update

The Longitude Prize is looking to help tackle the problem of antibiotic resistance with a £10 million prize fund for a diagnostic tool that can rule out antibiotic use or help identify an effective antibiotic to treat a patient.

Dr Chris Butler, Professor of Primary Care Medicine, University of Cardiff

Tamar Ghosh, Lead, Longitude Prize, Nesta



14:30 The Reimbursement debate: Understanding markets for pricing and reimbursement

- Is the unmet medical need a significant differentiator enough to drive reimbursement?
- Targeted therapy pricing: is the high price model here to stay?
- How to balance evidence based research and science with local policy decision making?
- Using 'risk-sharing' arrangements and value-based pricing approaches

John Hodgson, Editor, SCRIP (Chair)

Meindert Boysen, Programme Director Technology Appraisals, NICE

Prof. Sarah Garner, Associate Director, Research and Development, NICE

Mike Chambers, Head of Reimbursement and Value Demonstration, Market Access and Healthcare Solutions, GSK



15:15 The Analyst debate: What's Hot and What's Not in Life Sciences and Healthcare

- What is driving macro trends and specific opportunities for 2015?
- Where are the exciting new therapy areas and how can investors capitalise on them?
- Where are analysts pointing investors at the moment? What are some of the favourite stories?
- What lessons can be learned from the last 12 months and how does that affect 2015?

Mark Dunne, Reporter, Shares (Chair)

Stefan Hamill, Analyst, Healthcare and Life Sciences, Peel Hunt

Charles Weston, Director, Healthcare Equity Research, Numis Securities

Brian White, Head of Healthcare, Shore Capital

Sam Fazeli, Head of European Research, Pharmaceuticals Analyst, Bloomberg Intelligence

16:00 Close of congress followed by afternoon refreshments

REGISTER TODAY

biotechandmoney.com/london



CLOSED DOOR LISTED CEO FORUM

14:00pm - 16:00pm 3rd February 2015

Afternoon refreshments served within the room

- **How can the industry better educate and engage with generalist investors?**
 - Communications strategy: how to deliver the message
 - Understanding what investors are looking for and why
- **Where and how to raise funds**
 - How to raise funding for development projects in the very early stage
 - Where and how to raise funds when market sentiment is low
 - Where to target investors: retail vs institutional
 - How to target them
 - What works and what doesn't
 - How to raise funds from US and other sources
- **Single Asset, Multi Asset and Hybrid Business Models**
 - **Going global and expanding outside of the UK**

CEOs, CFOs and Chairmen from the following companies are in attendance including Circassia, Horizon Discovery, Clinigen, SkyePharma, Abzena, Scancell, Ablynx, Verona Pharma, Prosensa, Tigenix, Oxford Pharmascience, ReNeuron and Epistem with more to follow.

To join this private session you must be sat on the management board of a publicly listed company.

ATTENDANCE INCLUDES



Steve Harris
CEO
Circassia



Darrin Disley
CEO
Horizon
Discovery Group



Richard Vellacott
CFO
Horizon
Discovery Group



Richard Goodfellow
CEO
Scancell



Edwin Moses
CEO
Ablynx



Jan-Anders Karlsson
CEO
Verona Pharma



Olav Hellebo
CEO
ReNeuron



Michael Hunt
CFO
ReNeuron



Matthew Walls
CEO
Epistem



John Burt
CEO
Abzena



Tim Mitchell
CEO
Sareum



Peter George
CEO
Clinigen



Berndt Modig
CFO
Prosensa



Eduardo Bravo
CEO
Tigenix



Marcelo Bravo
CEO
Oxford
Pharmascience



Richard Marsden
CEO
Synairgen



Amber Bielecka
Partner
Consilium
Strategic
Communications

Life Science Futures '15 **GALA DINNER**

7.30pm February 3 | 155 Bishopsgate

With Special Guest Dinner Speakers

Prof. Dame Sally Davies
Chief Medical Officer of England

Anil Vaidya, Founder, SCANurse

Finalist in 2015

QUALCOMM
TRICORDER

XPRIZE®

A \$10m global competition to put
healthcare in the palm of your hand

BOOK YOUR SEAT TODAY

Add the Gala Dinner ticket to your online registration

NETWORKING AND 1-2-1

Biotech and Money London provides over 12 hours of networking time to hold those all important face to face meetings.

To ensure you maximise this time we provide attendees with access to Meeting Mojo, the congress 1-2-1 partnering App, to create an online profile and book meetings.

The App is a rapid, convenient way for you to start doing business before the event has even started.

Key features include:

- Detailed business profiling
- Auto meeting scheduler
- Printable schedules
- Optimised for desktop, tablets and smart phones

The congress provides a dedicated meeting room with tables and chairs for pre-arranged meetings plus many informal meeting points located throughout the congress venue.



**GET ACCESS
TO APP WHEN YOUR
REGISTER**

See whose coming by [clicking here](#)

SPONSORS AND PARTNERS

GOLD SPONSOR



Lilly makes medicines that help people live longer, healthier, more active lives. Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity and respect for people. Lilly has been operating in the UK since 1934 and is proud of its heritage in this country. London was host to our first office outside the United States and was closely followed by the first overseas manufacturing site, which opened in Basingstoke in 1939.

SILVER SPONSORS



The Oxford Academic Health Science Network brings together the NHS, universities, business, patients and the public to promote best health for our population and prosperity for our region. Breaking down traditional organisational boundaries and building stronger relationships between industry, scientific and academic communities – coupled with better knowledge exchange – will bring lasting benefits as best practice is spread quickly and widely across the NHS.



Stratagem IPM was formed in 1999 to respond to a developing need within the biotechnology industry for a clear and decisive strategic advice and management of intellectual property. Our service has been built on understanding and decisive action, not providing mere options and opinion and leaving the client to make the decision. From the original biotech foundation, we have significantly expanded both resources and industry coverage. The company now has commercially trained intellectual property experts with first-hand experience of several industries.



With strategically placed offices in the South of England, membership of Kreston International and a global network of independent accountants and business advisers, James Cowper is ideally placed to provide informed local, national and international advice. An integrated approach lies at the very heart of our business ethos. We consider all the angles when it comes to providing the widest levels of help, service and support for our clients, and apply the same approach to our people.



WilmerHale offers unparalleled legal representation across a comprehensive range of practice areas that are critical to the success of our clients. We offer a cutting-edge blend of capabilities that enables us to handle deals and cases of any size and complexity. In every area of practice, we bring insight, dedication to excellence, and commitment to client service needed for our clients to achieve their business objectives. Our five-department structure and team approach to service enable us to provide the highest level of responsiveness and access to lawyers.



Marks & Clerk is a well-established intellectual property firm with over 125 years' experience, advising clients in protecting patents, trade marks, designs and copyright. Nationally, we are the UK's largest firm of patent and trade mark attorneys and we have over 620 people worldwide. Our strong international presence is represented by our offices in Europe, Asia, Australia and the Americas. We don't just file patents and trade marks – we work proactively with innovative businesses to identify their IP assets and provide strategic advice to achieve full commercial value.

ASSOCIATE SPONSORS



Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. Imperial Innovations is a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation, and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors.



Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK.



Edinburgh BioQuarter is an academic medical centre with a focus on interdisciplinary research and translational medicine, with particular strengths in regenerative medicine and connected health. The campus brings together clinicians, industrialists, patients, scientists, state-of-the-art pre-clinical and clinical research facilities, and an academic teaching hospital on one campus. The BioQuarter links a broad range of leading companies and research institutions, providing world class facilities with one-stop access to a combination of pre-clinical and clinical excellence.



Royal Holloway, University of London can offer a wide range of opportunities to assist business with short term problems or long term strategic needs. Research and Enterprise helps business, the investment community and others to access our knowledge and expertise through contract research, consultancy, intellectual property licensing, and new business start-ups. We are always seeking opportunities to work with business in which our expertise can create new partnerships, accelerate the delivery of new products, processes or services or simply employ our unique combination of practical and leading-edge knowledge to enhance the performance of your business.



Biotech companies face a unique set of challenges. In IP development stages, Biotechs consume vast amounts of capital, so early investor trust is crucial. As the IP moves to reality and approaches the market, IPO and finally M&A activities become the focus; here again, trust is the key to success. Intralinks has built a reputation of trust in the Biotech community with a history of providing secure spaces and transactional tools for raising start-up capital; for keeping assets valuable and investor-ready; for taking companies public; and for exchanging critical, sensitive M&A information.



Coulter Partners is a retained executive search consultancy exclusively focused on Life Sciences. Founded by Bianca Coulter in 2003, we combine access to our global network of talent with meticulous contextual research to locate and deliver the best candidates available for assignments in every functional area of the Life Science sector. Our diverse, multi lingual team of consultants combines PhD level scientific understanding with deep sector experience. Our clients range from early stage, venture backed businesses to Global Pharmaceutical companies.

Contact Enrique Schindelheim, Vice President, Business Development to learn how we can build a bespoke sponsorship package around your needs.
Contact enrique@biotechandmoney.com or +44 (0)203 553 1092



Coté Orphan offers biopharmaceutical companies, private equity firms, and venture capital groups a comprehensive assessment of orphan products' regulatory risk and potential opportunity. Coté has the unique combination of clinical and regulatory expertise to design an orphan development pathway tailored to meet the requirements of FDA, EMA, and other regulatory agencies.



The ERA Consulting Group is one of the longest established and most experienced consulting groups serving the biopharmaceutical industry. Our emphasis is on consulting relating to quality, nonclinical and clinical aspects, both from the perspective of development strategy and regulatory requirements. Biopharmaceutical products and biomarkers are our particular speciality. ERA has the knowledge and experience to assist at all stages of product development.



The BioHub is a brand new, fully serviced biomedical laboratory specifically designed to provide entrepreneurs and innovative start-ups with access to affordable laboratory facilities and equipment. For a very attractive and fully inclusive price you can take a desk in a vibrant innovation office and a workstation in the fully serviced laboratory. As part of the package, we will provide you with full support in developing your innovative technology.

REAP THE BENEFITS OF BEING A COMMERCIAL PARTNER OF BIOTECH AND MONEY LONDON 2016

If you would like to discuss commercial partnership opportunities at **Biotech and Money London 2016, 2-3 February** or a community partnership role within Biotech and Money contact Enrique Schindelheim, VP, Business Development on +44 (0) 203 5531 092 or enrique@biotechandmoney.com

STRATEGIC PARTNERS



COMMUNICATIONS PARTNERS





MEDIA PARTNERS

Drugs&Dealers
magazine

BioPharm
Insight

 Current Partnering

DRUG DISCOVERY
TODAY

europaean
pharmaceutical
review

IPI
International Pharmaceutical Industry
Supporting the industry through communication

IP
LIFESCIENCES

 **iptechex**
pharmalicensing

Pharma**VOICE**

SCRIP
Intelligence

We've developed partnerships with our congress sponsors and partners to enable them to pass on exclusive discounts to their clients.

Contact the most appropriate sponsor or partner with which you are affiliated and ask for details of concessions that afford registration discounts to attend Biotech and Money London 2015.

The concession codes can be used at point of registration to save £££s.

BECOME A SPONSOR

THOUGHT LEAD

Are you looking for a platform to reinforce your Tier 1 position?

Do you see your company as a thought leader or pioneer?

Are you an innovator or disruptor in the field of Life Science?

EDUCATE

Do you see your company as offering best practice in the Life Science industry?

Is your company seen as a partner of choice amongst industry's elite?

Do you find speaking platforms an effective way of educating a client base?

RAISE AWARENESS

Are you a new entrant to the Life Science sector?

Are you finding it hard to make a name for yourself amongst established players?

Do you want to align your brand with the executive Life Science elite?

ENGAGE CLIENTS

Is your company looking to target a niche group of clients?

Can your company offer specific practical guidance and advice?

Do you find it beneficial to offer advice alongside leading industry players?

GENERATE LEADS

Is your company looking to expand it's current client list across a broad area?

Does your company prefer to be front of mind but without being intrusive?

Do you see conferences as an effective way to generate traffic?

WHO SPONSORS

Large Biotech / Large Pharma
Patent Attorneys / Law Firms
Global Consultant / Advisory
Assurance / Insurance
Investment Banks / Brokers
Venture Capital / Corporate Venture
Trade Associations

To discuss how Biotech and Money London can help your company achieve one or more of the above, contact Enrique Schindelheim, Vice President, Business Development to learn how we can help your business thrive.

Contact enrique@biotechandmoney.com or +44 (0)203 553 1092

DELEGATE REGISTRATION

Pre-Revenue Company*	Life science SME* & Pharma	Services Package
£455+VAT	£995+VAT	£1,995+VAT

The Last Earlybird Discount ended 23/01/15

Full 2-day conference ticket, access to 1-2-1 partnering App and drinks reception.



Ability to include a company showcase presentation on the online portal (Life science* only) for additional £100.



SME Only

Ability to upgrade to include Gala Dinner for additional £145.



PLUS standard lifetime Membership to Biotech and Money Community which affords subscription to newsletter, bi-monthly Drugs & Dealers magazine, access to exclusive content and discounts.



* Life science equates to Rx, Dx, MedTech and Digital Health

Book now

Book now

Book now

Individual benefits available

Investor

All SME* &
Pharma

Services
Package

3rd February Life Science Futures Gala Dinner and 2-day Conference Ticket for £195 (Investors only)



3rd February Life Science Futures Gala Dinner for £145.



Book now

Book now

Book now

BRING YOUR TEAM

Contact Enrique Schindelheim for details of Group booking discounts.
enrique@biotechandmoney.com or +44 (0)203 553 1092



biotechand**money** **LONDON**

Biotech and Money Ltd.

**The Euston Office
One Euston Square
40 Melton St
London NW1 2FD**

Telephone: +44 (0)203 574 4619
info@biotechandmoney.com